Interest of Freestyle Libre 2 as a Tool for Therapeutic Education in Recently Diagnosed Type 2 Diabetics Patients

Status: Recruiting
Location: See location...
Intervention Type: Other, Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Therapeutic patient education (TPE) is a key element in the management of people living with type 2 diabetes. The benefit of therapeutic education (TPE) has been clearly established on glycaemic control. Continuous interstitial glucose monitoring (CGM) can be considered as a TPE tool for people living with diabetes. A direct reading of the effects of diet and physical activity on glycaemic levels could have an impact on the initiation and maintenance of therapeutic lifestyle modifications. The investigators therefore propose a prospective randomised study in 2 arms : * a group of people living with diabetes receiving standard TPE vs * a group of people living with diabetes receiving standard TPE + FSL 28 days Ourmain objective is to determine the benefit of CGM on HbA1c at 3 months between 2 arms

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• recently diagnosed diabete mellitus (\<1 an) treated by non medical therapeutics and/or metformine

• \> 18 years old

• initial glycated hemoglobin between 7 and 8.5%

Locations
Other Locations
France
UHM Montpellier
RECRUITING
Montpellier
Contact Information
Primary
SULTAN Ariane, PU-PH
a-sultan@chu-montpellier.fr
+33467338402
Time Frame
Start Date: 2023-05-03
Estimated Completion Date: 2024-12-03
Participants
Target number of participants: 40
Treatments
Active_comparator: People living with diabete standard TPE
HBA1c at 3 and 6 months Therapeutic education Auto questionnary on Aviitam plateform at 3 and 6 months
Experimental: People living with diabete standard TPE + FSL 28 days
Continuous mesure of glucose (FSL2) during 28 days at enrollment Therapeutic education HBA1c at 3 and 6 months Auto questionnary on Aviitam plateform at 3 and 6 months~Auto questionnary on Aviitam plateform at 3 and 6 months
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Montpellier

This content was sourced from clinicaltrials.gov